<DOC>
	<DOCNO>NCT02443467</DOCNO>
	<brief_summary>This open-labeled , multi-center , prospective , non-comparative study safety Herceptin ( trastuzumab ) use adjuvant therapy patient early breast cancer previously receive antracycline therapy surgery .</brief_summary>
	<brief_title>A Study Determine Safety Tolerability Herceptin Adjuvant Therapy Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female patient &gt; = 18 year age Human Epidermal Growth Factor Receptor 2 ( HER2 ) neu overexpression Previously treat adjuvant antracycline contain chemotherapy Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % Eastern Cooperative Oncology Group ( ECOG ) score &lt; = 2 Life expectancy &gt; = 12 week Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % Advanced pulmonary disease Severe dyspnea Abnormal laboratory result within 14 day prior registration Peripheral neuropathy Presence Central Nervous System ( CNS ) metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>